Comprehensive genomic profiling of mucosal melanoma reveals novel fusion transcripts and dysregulation of cell‐cycle, MAPK, and PI3K pathways
It is proposed that MEK inhibitors may represent a relevant therapeutic option for BRAF fusions and non‐V600 BRAF mutant tumours, providing a novel strategy for this challenging disease.